FDA Product Code FDT: A Quantitative Audit of Duodenoscope Recalls and MAUDE Events

Duodenoscopes are critical medical instruments used in Endoscopic Retrograde Cholangiopancreatography (ERCP) procedures to diagnose and treat disorders of the biliary and pancreatic ductal systems. However, their complex design—especially the microscopic elevator mechanism used to guide therapeutic accessories—makes them notoriously difficult to clean, disinfect, and sterilize.

Under the FDA's medical device classification system, these devices are registered under product code FDT (Duodenoscope and accessories, flexible/rigid). Because of their history of patient-to-patient cross-contamination and bacterial transmission, they are among the most heavily scrutinized Class II devices on the market.

This article conducts an empirical, quantitative audit of the FDA's recall database and the Manufacturer and User Facility Device Experience (MAUDE) database to understand the safety patterns, manufacturer concentration, and clinical risks associated with product code FDT.

The Historical Recall Landscape: A 10-Year Audit

An analysis of the FDA's enforcement database reveals a total of 31 classified recalls associated with product code FDT from 2015 through 2025.

The recalls are highly concentrated among a small number of major medical device manufacturers. The distribution of recalls by recalling firm is detailed below:

Recalls by Year of Initiation

The peak of regulatory recalls occurred in 2015, following heightened FDA oversight and safety alerts regarding multidrug-resistant bacterial infections (such as Carbapenem-resistant Enterobacteriaceae, or CRE) linked to the elevator channel. A second wave occurred between 2021 and 2023, reflecting transitioning designs and single-use distal cap rollouts.

• 2015: 10 recalls
• 2016: 4 recalls
• 2017: 2 recalls
• 2018: 1 recall
• 2021: 4 recalls
• 2022: 4 recalls
• 2023: 5 recalls
• 2025: 1 recall

Root Cause Analysis of Recalls

The primary driver of recalls is device design, directly linked to the mechanical challenge of reprocessing.

• Device Design (13 recalls): Relates to cleaning challenges in the elevator wire channel and distal end crevices.
• Other (8 recalls): Miscellaneous issues, including adhesive deterioration.
• Under Investigation (4 recalls): Pending final root cause determination.
• Process Control (3 recalls): Manufacturing or assembly failures.
• Labeling Design (1 recall): Inadequate reprocessing instructions or IFU updates.
• No Marketing Application (1 recall): Clearing issues for design modifications.
• Process Design (1 recall): Process-design defects.

MAUDE Adverse Event Trends (2024–2025)

To evaluate real-world clinical performance, we analyzed the raw data from the FDA's MAUDE database for the years 2024 and 2025. The data demonstrates a significant upward trend in reported events under product code FDT, highlighting that reprocessing and mechanical failures remain active safety issues.

Year-Over-Year Volume Comparison

• 2024 Total Reports: 3,019
• 2025 Total Reports: 3,985 (a 32% increase year-over-year)

This increase does not necessarily prove an increase in patient infections; rather, it reflects heightened clinical awareness, updated reporting protocols, and the introduction of new disposable component designs (which have their own mechanical wear-and-tear reports).

Event Severity Breakdown

The vast majority of reports are filed as device malfunctions. However, a significant portion involve patient injuries and, in rare instances, patient deaths:

Brand and Model Concentration

The adverse event reports are heavily concentrated in Olympus’s dominant product lines. Below are the top brands reported in MAUDE under product code FDT:

2024 Top Brands:

1. EVIS EXERA III Duodenovideoscope (Olympus): 1,151 reports
2. EVIS EXERA II Duodenovideoscope (Olympus): 509 reports
3. Pentax Duodenoscope: 322 reports
4. EVIS LUCERA Duodenovideoscope (Olympus): 319 reports
5. Single Use Distal Cover (Olympus): 189 reports

2025 Top Brands:

1. EVIS EXERA III Duodenovideoscope (Olympus): 1,617 reports
2. EVIS LUCERA Duodenovideoscope (Olympus): 799 reports
3. EVIS EXERA II Duodenovideoscope (Olympus): 503 reports
4. EVIS LUCERA ELITE Duodenovideoscope (Olympus): 405 reports
5. Pentax Duodenoscope: 132 reports

Note: The high concentration of reports for Olympus devices is largely proportional to their overwhelming market share in flexible GI endoscopy.

Regulatory and Quality Implications for Manufacturers

For medical device manufacturers and quality managers working with endoscopic systems, the safety history of product code FDT provides three vital QMS and design lessons:

1. Design Out the Cleaning Risk: The FDA has actively encouraged the transition to duodenoscopes with disposable components (like single-use distal caps) or fully disposable duodenoscopes. If your product relies on a reusable complex mechanism, design validation must include rigorous, worst-case cleaning cycles (complying with ISO 17664 and FDA Reprocessing Guidance).
2. Monitor Passive Surveillance Data Sensibly: MAUDE is a passive surveillance database. It is prone to reporting bias, incomplete entries, and duplications. While it does not prove causality or provide incidence rates, it serves as an early-warning signal for mechanical wear-and-tear trends (e.g., fluid leaks, distal end cap cracking).
3. Anticipate Stricter Human Factors Validation: Cleanability is not just a laboratory test; it is a usability issue. Regulators require detailed Human Factors (HF) validation showing that clinical staff can successfully execute complex multi-step cleaning and sterilization protocols under real-world hospital pressures.

Sources

• FDA CDRH Product Classification Database (Product Code: FDT).
• FDA Recall Enforcement Reports (2015-2026 data extracts).
• FDA MAUDE Database (2024 and 2025 adverse event records).
• ISO 17664: Processing of health care products — Information to be provided by the medical device manufacturer for the processing of medical devices.